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Does a high dietary intake of resistant
starch affect glycaemic control and alter
the gut microbiome in women with gestational
diabetes? A randomised control trial protocol
Cathy Latino1,2,3* , Emily J. Gianatti4, Shailender Mehta5,6,7, Johnny Lo8, Amanda Devine1,2 and
Claus Christophersen1,9,10

Abstract
Background: Gestational Diabetes Mellitus (GDM) is prevalent with lasting health implications for the mother and
offspring. Medical nutrition therapy is the foundation of GDM management yet achieving optimal glycaemic control
often requires treatment with medications, like insulin. New dietary strategies to improve GDM management and
outcomes are required.
Gut dysbiosis is a feature of GDM pregnancies, therefore, dietary manipulation of the gut microbiota may offer a
new avenue for management. Resistant starch is a fermentable dietary fibre known to alter the gut microbiota and
enhance production of short-chain fatty acids. Evidence suggests that short-chain fatty acids improve glycaemia via
multiple mechanisms, however, this has not been evaluated in GDM.
Methods: An open-label, parallel-group design study will investigate whether a high dietary resistant starch intake
or resistant starch supplement improves glycaemic control and changes the gut microbiome compared with standard dietary advice in women with newly diagnosed GDM. Ninety women will be randomised to one of three groups
- standard dietary treatment for GDM (Control), a high resistant starch diet or a high resistant starch diet plus a 16 g
resistant starch supplement. Measurements taken at Baseline (24 to 30-weeks’ gestation), Day 10 and Day 56 (approximately 36 weeks’ gestation) will include fasting plasma glucose levels, microbial composition and short-chain fatty
acid concentrations in stool, 3-day dietary intake records and bowel symptoms questionnaires. One-week post-natal
data collection will include microbial composition and short-chain fatty acid concentrations of maternal and neonatal
stools, microbial composition of breastmilk, birthweight, maternal and neonatal outcomes. Mixed model analysis of
variance will assess change in glycaemia and permutation-based multivariate analysis of variance will assess changes
in microbial composition within and between intervention groups. Distance-based linear modelling will identify correlation between change in stool microbiota, short-chain fatty acids and measures of glycaemia.
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Discussion: To improve outcomes for GDM dyads, evaluation of a high dietary intake of resistant starch to improve
glycaemia through the gut microbiome needs to be established. This will expand the dietary interventions available
to manage GDM without medication.
Trial registration: Australian New Zealand Clinical Trial Registry, ACTRN12620000968976p. Registered 28 September
2020
Keywords: Gestational diabetes, Diet therapy, Resistant starch, Gut microbiome, Fasting glucose, Short-chain fatty
acids

Background
Gestational Diabetes (GDM) is a state of glucose intolerance first discovered in pregnancy via routine screening
undertaken between 24 and 28 weeks of gestation [1]. It is
largely a disease of insulin resistance (IR) with the prevalence increasing in parallel with increasing rates of obesity [2]. Optimal glycaemic control reduces many of the
risks associated with GDM [3–5] including preeclampsia,
macrosomia, large for gestational age, shoulder dystocia
and neonatal hypoglycaemia [2, 6]. Offspring of women
with GDM also have a higher risk of obesity and impaired
glucose metabolism [2, 7–10]. Mothers with a history of
GDM have an increased risk of developing cardiovascular disease [11] and type 2 diabetes (T2DM) [12].
Current evidence-based dietary strategies are often
insufficient to optimise glycaemia [13] therefore, in some
populations, more than half of GDM women require
pharmacotherapy to control their blood glucose [14–17].
This increases the burden to the woman and health system through additional monitoring and clinic appointments to ameliorate the risk [18]. Hence, new dietary
strategies are required to improve outcomes for women
and their offspring [5] and to reduce health expenditure
[18].
Similar to T2DM [19, 20], gut dysbiosis has been
reported as a feature of GDM pregnancies and associated
with higher blood glucose levels [21–23]. Evidence to
support the relationship between diet, the gut microbiota, IR and glycaemic control in T2DM is strengthening
[24–30]. Hence, specific changes to the diet can modify
the gut microbiota [31, 32] suggesting that dietary modifications which impact the maternal gut microbiota and
metabolome are potential therapies to improve glycaemia
in GDM [21, 33–36].
Gut microbiota and glycaemic control are known to
be altered by fermentable dietary fibres such as resistant
starch (RS) [28, 29, 37, 38]. A systematic review by Colantonio, Werner and Brown [29] concluded that foods
with prebiotic properties, such as RS, may improve glycaemic control in women with T2DM. More specifically,
a meta-analysis of RS supplementation by Wang et al.
[28] showed improvements in fasting glucose and IR,
particularly in overweight or obese people with diabetes.

Microbial fermentation of RS increases the production of
short chain fatty acids (SCFA) [39]. SCFA are thought to
improve glycaemic control through multiple mechanisms
[20], discussed later, suggesting that the manipulation
of the microbiome using RS may be a novel therapeutic
option for reducing the severity of GDM.
This study will evaluate whether a high dietary RS
intake from diagnosis with GDM can improve maternal
glycaemic control; impacts the maternal and/or neonatal gut microbiota, faecal SCFA production, maternal
and neonatal health outcomes; and collect information
to determine the health economic benefits of improvement of dyads health outcomes that result from this
intervention.
We hypothesise that compared with standard GDM
dietary advice, women with a high dietary intake of RS
from the diagnosis of GDM will show a reduction in
fasting blood glucose (FBG) levels and other measures
of glycaemic control. This will reduce the percentage of
women who require insulin and improve maternal and
foetal outcomes.

Methods
Overview of study design

An open-label, parallel-group design study will be used
to investigate whether a higher RS intake from diagnosis
of GDM changes the gut microbiome and improves glycaemic control compared with standard dietary advice.
Educating women to consume a diet consistent with evidence-based recommendations for the dietary management of GDM [40] was chosen as the comparator group
as it is safe for participants and this study aims to evaluate whether the interventions are more effective than
usual care.
Participants will enter the trial at diagnosis with GDM
between 24 and 30 weeks of gestation. Informed written consent will be obtained by the Principal Investigator (PI) prior to randomisation into one of three dietary
treatment groups – standard dietary treatment for GDM
(Control), a high RS diet (RS Diet) or a high RS diet plus
an RS supplement (RS Supp). The dietary intervention
will continue until delivery. Measurements will be taken
at Baseline over Days 1–3 (where they will be between 24
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Fig. 1 Flow diagram of study design, participant recruitment and journey. Note: GDM = Gestational Diabetes Mellitus

to 36-weeks’ gestation), Day 10, Day 56 (approximately
36-weeks’ gestation) and 1-week after delivery (Fig. 1).
Study population

Participants will be women who are newly diagnosed
with GDM and plan to deliver their baby at a tertiary hospital in Western Australia, where all study visits and routine antenatal care will be undertaken. Inclusion criteria
include women diagnosed with GDM through a routine
75 g Oral Glucose Tolerance Test (OGTT) between 24
and 30 weeks of pregnancy and ≥ 18 years of age. A diagnosis of GDM is made using the International Association of Diabetes in Pregnancy Study Groups (IADPSG)
diagnostic criteria of one or more values reaching
the following levels – Fasting glucose ≥5.1 mmol/L,
1-h ≥ 10.0 mmol/L, 2-h ≥ 8.5 mmol/L [41].

Participants will be excluded if they have an early
diagnosis of GDM before 24 weeks; Overt Diabetes in
Pregnancy; Type 1 Diabetes; T2DM; poorly controlled
hypothyroidism; Graves’ Disease; twin pregnancy;
breastfeeding; vegetarian; vegan; irritable bowel syndrome; inflammatory bowel disease; previous bariatric
surgery; history of an eating disorder; allergy to adhesives; antibiotic use in the past 3 months; use of steroids,
antipsychotics, metformin, laxatives, fibre supplements
or probiotic supplement; any major medical disorder; any
psychosocial issues likely to impact on ability to adhere
to study protocol.
Demographic information will be collected from the
digital medical record (DMR) and participants will complete a demographic questionnaire at Baseline to obtain
information on ethnicity, medical and obstetric history,
medication and dietary supplement usage.
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Sample size

In a study by Asemi et al. [42], the average woman with
GDM has a mean FBG of 5.175 ± 0.86 mmol/L. In RS
supplementation trials, a difference in FBG as large as
0.4 mmol/L has been observed between control and RS
supplemented groups [38]. This study aims to demonstrate a reduction in FBG of 0.3 mmol/L, which corresponds to a small to medium Cohen’s effect size
(d = 0.35). Based on a repeated-measures design with
three groups (Control, RS Diet, RS Supp) and three time
points (Baseline, Day 10 and approximately Day 56), a
minimum sample size of 69 (i.e., 23 per group) is required
to detect a small to medium within-between interaction
effect (Cohen’s f = 0.175) at 80% power and 5% level of
significance. Allowing for an attrition rate of around
30%, the final total sample size required is 90 (i.e., 30
per group). Women who commence insulin therapy will
remain in the study.
Recruitment

Women with newly diagnosed GDM who are potentially
eligible to participate in the study will be given a study
flyer. When attending clinic for standard GDM education, the Principal Investigator (PI) will explain the study
and screen for eligibility, then invite eligible women to
participate and provide written consent. The Participant
Information Letter is provided in Supplement 1 and Participant Consent form in Supplement 2. Consent for data
to be collected on the neonate will also be obtained.
Participant retention will be supported through undertaking study requirements at routine antenatal visits,
complimentary parking, text reminders, supportive
telephone contact from the PI between widely spaced
appointments, and regular contact with the obstetric and
midwifery team. Participants who withdraw consent to
provide stool and urine samples will be given the option
of providing fasting glucose samples.
Randomisation

Stratified randomisation of participants based on prepregnancy Body Mass Index (BMI) category will be utilised. BMI categories are Healthy (BMI 18.5–24.9 kg/
m2), Overweight (BMI 25–29.9 kg/m2) and Obese
(BMI ≥ 30 kg/m2). A computer-generated random
sequence was created by a statistician and repeating
blocks of three groups per three BMI categories were
used to generate group allocation order. Eligible participants will be randomised by the PI to the next predetermined group, sequentially as consented. Neither the
participants nor the investigators will or can be blinded
to the treatment allocated.

Page 4 of 13

Intervention
Dietary intervention

All women will receive standard GDM dietary advice
in line with evidence-based guidelines [2, 40, 43, 44].
Women will be encouraged to consume a minimum carbohydrate intake of 175 g per day, from mostly low glycaemic sources, distributed across the day over three
meals and three snacks. The dietary advice will promote
a low saturated fat intake and higher consumption of vegetables, fruit, dairy and whole grains.
After Baseline data are collected, women who are randomised to either of the two dietary intervention groups
(RS Diet & RS Supp) will receive additional dietary education on consuming a high RS diet commencing on Day
3. All RS dietary education will be conducted by the PI
who is an experienced Accredited Practising Dietitian
(APD). A standardised teaching plan (Supplement 3)
and education materials will be utilised (Supplements
4 & 5). Participants will be provided with written material including a Gut Feeling cookbook [45] and sample
menus, as well as some non-perishable samples of high
RS foods to allow for immediate adoption of the diet.
Dietary RS will be measured at Baseline, Day 10 and Day
56 using 3-day weighed food records (Supplement 6).
Evidence of compliance with the high RS diet will also be
monitored via urine samples for metabolomic analysis
and change in stool microbiota at the same timepoints.
Participants will be asked to continue the high RS diet
until the delivery of their child.
The RS education tools and strategies have been
piloted in a non-pregnant population and achieved a
median increase in dietary RS intake of ≥6.6 g RS per day
(unpublished data). The typical intake of RS in Australian women aged 19–44 years has been estimated to range
from 2.9–8.3 g per day [46]. Similarly, recent data from
the United States estimated the mean daily intake of RS
to be 1.9 g per 1000 kcal for women of this age [47], which
would equate to 3.8–5.7 g per day.
RS supplement

The RS Supp group will consume an RS supplement of high-amylose maize (HAMS) type 2 resistant
starch. Participants will be given a 600 g tub of HAMS
each fortnight, along with a 40 ml scoop. They will be
instructed and provided with written material (Supplement 7) on how to prepare and incorporate the RS
supplement into cool fluids or foods in their diet. As
with all low-digestible carbohydrates, gastrointestinal
(GI) discomfort is a known side effect of rapid introduction of RS, therefore, participants will introduce
HAMS over a two-day adjustment period. They will be
instructed to consume 1 scoop (20 g) per day for 2 days,
taking half in the morning and the rest at night. Then,
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increasing to a dose of 1 scoop (20 g) morning and night
for the remainder of their pregnancy. The RS supplement contains 40% RS type 2. The final amount of RS in
the 40 g of HAMS per day will be 16 g, which is below
the level of 45 g per day of RS supplementation that is
known to be tolerated with minimal side effects, most
of which are flatulence [48]. Intakes of up to 80 g RS per
day have been tolerated without diarrhoea [48]. Those
in the high RS diet plus RS supplement are unlikely to
achieve this amount. Consumption and compliance
of the RS supplement will be monitored by weight of
unconsumed HAMS returned fortnightly. Participants
will use a daily RS supplement diary to record intake as

an additional measure of compliance. We have shown
in a recent 2-week feasibility study, 100% compliance
with consumption of the RS supplement and minimal
GI side effects in 10 female participants with prediabetes or T2DM (unpublished). GI tolerance of the supplement will be measured via a daily bowel symptom diary
for the first 10 days and Days 47 to 56.
Participants can withdraw from the study at any time
for any reason. Participants will be withdrawn by the
investigator if they commence antibiotics, steroids, metformin or if they can no longer comply with the study’s
schedule of assessments (Table 1).

Table 1 Participant measurements and collection summary
Day 1

Recruitment & consent

√

Randomisation of subjects

√

Attend clinic

√

Self-monitoring blood glucose data collection
FreeStyle Libre Pro application

Day 3

Day 10

√

√

√

√

Day 28

Day 42

Day 56

√

√

Day 7
postpartum

√

√

√

Questionnaires:
medical Hx

√

medication

√

GI symptoms

√

√

√

Quality of Life SF36

√

√

√

√

√

3-day weighed food records collected

√

√

√

Bowel symptoms, RS supplement, medication &
exercise diary collected

√

√

√

H2 breath test

√

√

√

√

√

√

√

√

√

√

√

Weight measured

√

Fasting Bloods
Maternal stool samples
Maternal urine sample

√
√

Neonatal stool sample
Neonatal urine sample

√

Breastmilk sample

√

Study instructions and materials
RS diet education

√

supplement regime if applicable

√

Reminder phone call or text
Assessment of Medical Records for
adverse outcomes
delivery method
birth weight, length
feeding method
NICU admission
length of stay
Note: RS Resistant starch, NICU Neonatal Intensive Care Unit

√
√
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Primary outcome
Fasting blood glucose

The primary outcome of this study will be a reduction in median FBG from Baseline, within and between
groups. Baseline FBG will be recorded from the diagnostic OGTT results [41]. Subsequent venous blood samples
will be collected after an overnight fast at Day 10 and Day
56 and analysed for FBG following protocols from the
National Association of Testing Laboratories. FBG within
treatment targets (< 5.1 mmol/L) [49] is the measure of
glycaemic control that has been most difficult to achieve
with standard GDM diet and lifestyle interventions and
therefore the variable most likely to indicate the need
for medical therapy, such as insulin [50]. If FBGL below
5.1 mmol/L is not achieved by Day 10, insulin therapy will
commence. Participants treated with insulin will remain
in the study.
Routinely women will receive self-monitoring of blood
glucose (SMBG) education. Participants will be provided
with an SMBG meter and instructed on measuring blood
glucose levels four times daily (FBG and 2-h post-prandially). The SMBG meters used will be either Contour Next
(Ascensia Diabetes Care, Switzerland), Accu-Chek Guide
(Roche Diabetes Care, Switzerland) or One Touch Verio
(LifeScan, USA) and meet International Organization for
Standardization (ISO) standards for accuracy. Data from
these models will be uploaded via the Diasend Uploader
(Glooko, USA). FBG will be monitored on the first 2 days
and averaged to provide a Baseline measure. This will be
compared to the moving averages over the subsequent
8 days of testing, and then again between Days 48 and 56,
across the three dietary groups (Control, RS Diet and RS
Supp) using mixed model ANOVA with group-by-time
interaction.
Secondary outcomes
Post‑prandial glucose

Post-prandial blood glucose (PPBG) will be measured
by participants using SMBG three times per day for
three consecutive days. The change in mean 2-h PPBG
and frequency of PPBG levels above the target for each
mealtime will be calculated and compared within and
between groups at Baseline (Day 1–3), Days 8–10 and
Days 54–56. Two-hour PPBG excursions of 6.7 mmol/L
or more are considered above the target for optimal pregnancy outcomes [49]. Elevated PPBG are associated with
preeclampsia, caesarean section delivery, large for gestational age (LGA), neonatal hypoglycaemia [6] and childhood glucose and IR [10].
Time in range for glucose

Participants will be provided with and trained in the use
of, a FreeStyle Libre Pro glucose sensor. On Day 1 and
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Day 42, using aseptic technique and following the manufacturer’s procedure, one FreeStyle Libre Pro glucose
sensor (Abbott Diabetes Care, California, USA) will be
applied to the mid-triceps area of each participant using
a spring-loaded application device supplied with the sensor. A fine, flexible, 5 mm cannula extends from the sensor into the interstitial fluid and the sensor is secured on
the skin via an attached adhesive pad. The sensors can
be worn in the shower, whilst swimming or exercising.
The sensors will be electronically paired with a FreeStyle
Libre Pro reader through which the glucose data can be
downloaded. The sensors continuously provide interstitial fluid glucose data every 15 min for 14 days and will
allow for more accurate assessment of FBG, 2-h PPBG,
frequency of 2-h PPBG levels elevated to ≥6.7 mmol/L
and time in range (TIR) of optimal blood glucose levels
of 3.5–7.8 mmol/L [51]. FreeStyle Libre glucose sensors
have been validated in pregnancy against SMBG and
found to be safe, accurate and acceptable to users [52].
Ethics approval has been obtained for use of FreeStyle
Libre sensors in this study, however, funding for this is to
be secured.
Requirement for insulin treatment

Data from the participants’ DMR will determine the percentage of women requiring insulin to control blood glucose levels at Day 10 and Day 56 compared to the control
group. Participants who require insulin will remain in the
study and all samples will be collected. The commencement of insulin to manage glycaemia requires more
health care monitoring and intervention, adding burden
to the woman and the health care system [18].
Microbiota

Maternal gut microbiota All participants will receive
written information (Supplement 8) and be instructed
on the procedure for collection and storage of the first
stool passed in the day at Baseline, Day 10, Day 56- and
one-week post-partum. Each participant will be provided with a cooler and ice bricks for storage and transportation of stool samples. Upon receipt, stools samples
will be weighed to the nearest 0.1 g on an electric balance (A&D, Japan) then immediately stored in a − 80 °C
freezer. Stools will be thawed at 4 °C then homogenized
and aliquoted, then restored at − 80 °C until analysed for
microbial composition and their SCFA metabolites. This
procedure will be repeated for each time point.
Microbial analyses will be performed at the Western
Australian Human Microbiome Collaboration Centre
at Curtin University. DNA will be extracted using the
QIAamp PowerFecal Pro DNA kit (Qiagen). Microbiome
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signatures will be generated using the Illumina MiSeq
platform barcoded V4 primer (515–806) targeting a
hypervariable region of the 16S rRNA gene. Polymerase
chain reaction free (PCR-free) ligation protocol will be
deployed for library building. Samples will be sequenced
to a depth of a minimum 20,000 reads, which is sufficient
to identify microbes to a genus/species level. Quality
control samples and mock communities will be included
in the analysis from sample collection to sequence analysis. Sequence read quality will initially be assessed with
FastQC before demultiplexing and pre-processing by
GHAPv2, an in-house tool. Cutadapt [53] will be used for
the removal of all non-biological sequences. DADA2 [54]
will then be used for quality filtering, error correction,
amplicon sequence variants (ASVs) picking. A trained
Naïve Bayes classifier will then assign ASVs to genus/
species against a curated database of microbial reference
sequences such as the Ribosomal Database Project (RDP)
[55] or Genome Taxonomy Database [56].
An increase in RS consumption is known to alter the gut
microbiota in non-GDM populations [37]. An alteration from Baseline in stool microbial composition in
RS groups towards a symbiotic composition compared
with the control group will indicate that the increased
RS consumption affects the microbiota of a woman with
GDM and would indicate compliance with the RS dietary
intervention.
Neonatal gut microbiota A neonatal stool sample will
be collected one-week post-partum for microbial analysis
as above. These will be used to evaluate the effect of RS
supplementation on microbiome seeding of the infants in
relation to the maternal microbial composition. The neonatal sample will be collected and stored by the mother at
home as per a standard procedure that will be provided
with the stool sample kits before discharge (Supplement
9). In brief, the lid of the stool sample pot will contain an
integrated scoop that is used to collect the majority of
the neonate’s stool sample from the nappy. The sample
pot will be capped with the filled scoop, placed immediately into a cooler lined with ice bricks and delivered to
the hospital within 24-h. It will be weighed and stored at
− 80 °C immediately.
Breast milk microbiota If the mother has chosen to
breastfeed, a 10 ml breast milk sample will be collected at
one-week post-partum for microbial analysis. A standard
procedure and collection tubes will be provided before
discharge (Supplement 10). Briefly, after breastfeeding
her infant, washing hands with soapy water and donning gloves, the mother will express breastmilk into two
5 ml sterile tubes from the same breast by hand or using a
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sterilised breast pump. Approximately 3–4 ml will be collected in each tube. Breastmilk samples will be frozen at
home then delivered to the hospital in a cooler with ice
bricks and immediately stored at − 80 °C until analysis for
microbial composition at the Western Australian Human
Microbiome Collaboration Centre at Curtin University.
The microbiota of breast milk is postulated to be a determinant of the neonatal microbiota [57].
Faecal SCFA

The maternal stool samples collected, processed and
stored as outlined above at Baseline, Day 10, Day 56 and
one-week post-partum will be analysed for concentrations of SCFA (acetate, butyrate and propionate). The
method of analysis will use gas chromatography and
mass spectrometry as detailed by Stinson, Boyce [58].
An increase from Baseline in mean SCFA is a marker of
increased gut microbiota fermentation. SCFA are thought
to be the primary metabolites by which the microbiota
affects glycaemic control [19–21, 59–62]. Neonatal stool
samples collected at one-week post-partum will also be
analysed for SCFA content using the above method.
Anthropometric measurements

Maternal height will be measured (to the nearest 0.1 cm)
by a trained nurse at Baseline using a stadiometer (Seca,
Germany). Weight will be measured (to the nearest
0.1 kg) at Baseline, Day 10 and Day 56 using scales (A & D
Medical, Japan). Excessive gestational weight gain compromises maternal glycaemic control and therefore it is
important to ensure this does not differ between groups.
The birth weight of the neonates’ will be measured to
the nearest 5 g by a trained midwife using the scales of
a Panda Warmer (General Electric Healthcare, USA).
Length at birth will be measured to the nearest centimetre using a metric tape measure. Anthropometric data
will be collected from the DMR of the neonates to determine the mean birth weight, Ponderal Index [weight (g)
÷ length (cm)3] and percentage of LGA or macrosomic
neonates of the intervention groups (RS Diet & RS Supp)
compared to the control group. High birth weights are
associated with shoulder dystocia, caesarean section
delivery, post-partum haemorrhage, childhood obesity, and insulin resistance [63] and therefore one of the
main complications of GDM that all treatments aim to
improve.
Gastrointestinal tolerance

Bowel symptoms questionnaire Mild gastrointestinal
side effects are expected with a high consumption of
RS. A GI symptoms questionnaire adapted from Francis
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[64] will be administered at Baseline, Day 10 and Day
56 (Supplement 11). The questionnaire contains a visual
analogue scale between 0 and 100 for each of four symptoms, generating a total score of up to 400. Participant
responses will be measured manually from the zero mark
by the PI and converted to a score out of 100. Scores will
be used to evaluate the effect of the interventions on GI
comfort and function.
Bowel symptoms record Participants will be asked to
keep a bowel symptoms diary at Baseline (Day 1 to 3),
Days 8 to 10 and Days 54 to 56 to assess tolerance of
the diet and supplement (Supplement 12). This will be
returned at the Day 10 and Day 56 study visits. They will
record the frequency of bowel movements, rate each
movement on a scale of 1 to 7 for consistency using the
Bristol Stool Chart [65] and ease of stool passage on a
scale of 1–5 where 1 = very easy and 5 = very difficult
[66]. The diary includes a subjective scoring of symptoms of flatulence, borborygmus, abdominal cramping
and distention, nausea, diarrhoea, constipation. Scores
will be chosen from a scale of 0 to 3, where 0 is for no
symptoms beyond their normal and 3 is a rating of severe
symptoms, an evaluation method used previously by
other researchers [67]. The average composite score for
individuals’ first 2 days prior to the intervention will
be compared to the average score for the second week
of the study to establish whether there is a statistically
significant difference within individuals and between
groups. Scores for individual symptoms will be similarly
complied to compare differences within individuals and
between groups. This scoring system will also be used as
one mechanism for identifying and rating adverse events
(AE), along with participants self-reporting of AE. A
score of 3 (severe) will be considered an AE and reported
in the publications resulting from this trial. A small feasibility study in women with prediabetes or diet controlled
T2DM (n = 10) trialled the high RS diet and the RS supplement and they were well tolerated (unpublished data).
Participants will be encouraged to report any AE to the
PI who will escalate to the appropriate health care professional and human ethics committee immediately.

Resistant Starch intake

Food records All participants will be instructed by the
APD to keep a 3-day weighed food record at Baseline
(Days 1–3), Days 8–10 and Days 54–56 for assessment of
mean RS intake (Supplement 6). Food records will be collected at the next study visit. Alternatively, participants
can choose to log their food intake using the Research
Food Diary app (Xyris Software, Queensland, Australia).
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To aid in the accurate measurement of food consumed,
kitchen scales (Propert, China), metric measuring cups
and measuring spoons will be lent to participants. Nutrient analysis of food records will be completed using
FoodWorks 10 (Xyris Software, Queensland, Australia).
Databases on RS content of foods are limited and RS content varies widely depending on cultivars, growing conditions, country of origin, food processing, preparation and
storage methods, and methods of analysis [61]. Published
RS values for individual foods vary widely. Therefore, a
database created from the minimum and maximum RS
values published by various authors [46, 68–70] has been
created by Edith Cowan University researchers and will
be utilised in this study to calculate RS intake. This database has previously been used for nutrition research [71].
RS supplement consumption diary Participants will
be provided with a supplement diary as one measure of
compliance with the RS regime (Supplement 13). Compliance with the study protocol will be achieved if at least
80% of the RS supplement doses have been recorded as
consumed over the study period.
RS supplement returned Weighed portions of the RS
supplement will be provided to participants fortnightly.
Unconsumed RS supplement will be returned by participants and weighed on kitchen scales (Propert, China), to
assess the percentage consumed and subsequent compliance with the RS consumption target.
Breath H2 A handheld hydrogen breath analyser (H2
Check, MD Diagnostics Ltd., UK) will be used to assess
change in H2 production with the RS interventions. This will
also be used as a measure of compliance with the RS diet and
RS supplement. Breath H
 2 measurements will be taken Day
3, Day 10 and Day 56. Ethics approval has been obtained to
collect Breath H2 data, however, funding has to be secured.
Health‑related quality of life

Participants will complete the RAND 36-Item Health
Survey 1.0 (SF-36) [72] at Baseline and Day 10 and Day
56. Scoring will be completed and standardised with Australian reference ranges using the methods and data from
the Australian Longitudinal Study of Women’s Health
[73]. Scores will determine if the health-related quality of
life is maintained across nine health domains during the
intervention.
Metabolomics

Blood (maternal) Fasting maternal blood samples will
be collected on Day 10 and Day 56. Phlebotomy and
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processing will be performed by a registered pathology
service following their standard operating procedures
for handling blood. In addition to a fasting glucose test,
8.5 ml of blood will be drawn into a serum tube, centrifuged, 1 ml aliquots transferred into 4 tubes and stored in
a − 80 °C freezer for analysis of SCFA content, lipids and
metabolomics.
Urine (maternal and neonatal) First void maternal
urine samples will be collected as per a standard procedure (Supplement 14) at Baseline, Day 10 and Day 56
and stored at − 80 °C until metabolomic analysis can be
performed at the Australian National Phenome Centre, Western Australia. Urinary metabolomic markers of
foods consumed will be used to assess compliance with
the consumption of high RS foods by the RS intervention groups. Additionally, metabolomic analysis will seek
to identify additional biochemical markers that enable a
better understanding of the systems biology effects of the
intervention.
A neonatal urine sample for metabolomic analysis will
be collected by the mother 1-week post-partum as per
a standard procedure that will be provided with the
stool sample kits before discharge (Supplement 15).
Maternal and neonatal outcomes and cost of antenatal care

Maternal and neonatal outcomes data will be collected
from the DMR after discharge. Diagnosis Related
Group (DRG) [74] data will be collected for calculation
of hospital costs. Maternal outcome data collection
will include the number of ANC clinic visits, Maternal
Foetal Assessment Unit visits, antenatal admissions,
delivery method, post-partum maternal length of stay,
and feeding method on discharge.
After discharge, data on admission to the Neonatal Intensive Care Unit (NICU), reason for admission
and length of stay will be collected from the DMR of
the infant to determine the frequency of admissions
to NICU in the intervention groups compared to the
control group. NICU admission for neonatal hypoglycaemia or respiratory support is a known complication
in babies of GDM mothers and is one of our secondary outcomes for the study. There is a linear relationship between glycaemia and admissions to NICU in
offspring of women with GDM [6]. We will record this
outcome and collect neonatal samples as and when
the baby’s clinical condition allows. We accept that
research on pregnant women raises particular safety
concerns. It is noteworthy that our intervention is safe
and we do not expect serious adverse events as a direct
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result of the intervention. We expect neonatal deaths
to be not different from the general population.
Data management

Individually identifiable data will be coded as soon as
possible. Data and codes will be kept in separate lockable filing cabinets within a swipe card accessible office
and access to the data will be restricted to the research
team. Electronic data will be kept in a de-identified format and stored on a password-protected computer or
secure server and for a minimum of 25 years. At the end
of the retention period, data files and any hard copy
source data will be deleted/shredded as per the South
Metropolitan Health Service and Edith Cowan University data management requirements. Data collected on
participants who later withdraw will be used in analysis
if required unless consent to use it has been withdrawn.
The trial investigators/institutions will permit trialrelated monitoring, audits, and regulatory inspections,
providing direct access to source data/documents.
This may include, but not limited to, review by Human
Research Ethics Committees and institutional governance review bodies.
Statistical analyses

Baseline demographic and outcome variables will
be described and compared for differences between
groups. Continuous variables will be described as
mean ± standard deviation (SD) and nominal and
ordinal variables as frequencies and proportions. All
continuous variables will be examined for normality
using the Shapiro-Wilk test. Descriptive statistics for
non-normal continuous variables will be presented as
median ± interquartile range (IQR).
FBG and PPBG will be monitored on the first 2 days
and averaged to provide a Baseline measure of each outcome. These will be compared to those measured over
the subsequent 8 days, and then again between Days
48 and 56, across the three dietary groups (Control,
RS Diet and RS Supp) using linear mixed modelling
with group-by-time interaction. Analysis will assess if
a 0.3 mmol/L reduction is achieved. Demographic variables such as age, pre-pregnancy BMI, parity and ethnicity will be adjusted in the model. Statistical analyses
will be performed using SPSS® (Statistical Package for
Social Sciences, version 27 for Windows).
The number of PPBG excursions experienced by a
participant per day between Days 4 to 10 will be examined and compared relative to the number determined
at their Baseline over the first 2 days of the usual care
diet. Generalised Mixed Modelling will be utilised to
assess whether a dietary change reduces the frequency
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of PPBG excursions as compared with norm with
adjustments for relevant demographic variables.
Different R packages and PRIMER 7 (Quest Research,
NZ), a non-parametric statistical software package, will
be used to assess change within and between groups for
microbial composition. Distance Based Linear Modelling (DistLM) will be used to look for a correlation
between change in stool microbiota or SCFA & measures of glycaemia.
Direct and indirect costs savings related to any reduction in insulin treatment or improvements in maternal
and neonatal outcomes will be calculated from DRG
codes, Weighted Activity Units (WAU) and the National
Efficient Price (NEP) and reported [74].
Missing data will be treated in statistical analysis as
missing and coded as 999 or left blank, so as not to affect
the accuracy of the analysis. Prior to any statistical analysis, all data will be explored for outliers. Any outliers
found will be cross-checked with the source file. Any true
outliers will be checked with the clinician before being
removed/left in the dataset.

Discussion
GDM is prevalent and optimal glycaemic control offers
health benefits to the mother and child [2]. Current dietary strategies have proven positive outcomes [5, 40] but
are not effective enough for more than half of women
to avoid insulin therapy [14]. Additionally, women
post-GDM and their offspring remain at greater risk of
metabolic health problems over their lifetimes [2]. A
cost-effective lifestyle solution to further improve glycaemic control and minimise the requirement for medication is necessary to both achieve better maternal and
neonatal outcomes and to reduce the burden on health
care systems [18]. Therefore, novel dietary strategies are
required.
Gut dysbiosis has been reported as a feature of GDM
pregnancies [21–23] and it is established that dietary
intake of fermentable fibres, such as RS, changes the gut
microbiota and metabolome [39, 75]. RS supplementation has also been shown to improve glycaemic control
in prediabetes and type 2 diabetes [28], with the likely
mechanism via SCFA produced during the fermentation
of RS by the gut microbiota [20]. The three main SCFA’s
acetate, propionate and butyrate have all been found to
play an essential role in maintaining a healthy gut, insulin resistance and insulin sensitivity. Butyrate enhances
gut wall integrity, reducing gut permeability to endotoxins thereby lessening adipose tissue inflammation and
IR [19–21, 59, 60]. Butyrate is also thought to stimulate
colonic L-cells to release glucagon-like peptide-1 (GLP1), and other gut hormones, which improve glucose
homeostasis through increasing glucose-dependent
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insulin secretion, suppressing glucagon secretion, slowing gastric emptying and reducing appetite [20, 76, 77].
Acetate and propionate are directly associated with
improved insulin sensitivity of adipose and skeletal muscle cells [61, 62].
Studies have characterised gut microbiome changes
in the GDM population [21, 22, 35, 78, 79], assessed
the effect of dietary manipulations on the maternal gut
microbiome [35, 80, 81] or the relationship between the
microbiome and glycaemic control in GDM [22, 23, 78,
79, 82]. However, very few randomised control trials
have examined all these parameters in the same study,
using a diet intervention to manipulate the gut microbiome to improve glycaemia and achieve better outcomes
in a GDM population. For instance, Mokkala et al. [81]
showed that fish oil and probiotic supplements were not
effective in altering the microbiome or serum glucose in
overweight and obese GDM women. To our knowledge,
there are no studies that have investigated the relationship between dietary RS intake, the gut microbiome,
glycaemic control and maternal and foetal outcomes in
pregnancies affected by GDM, therefore, this needs to
be explored as a lifestyle and economical approach to
management.
This open-label, parallel-group design study will build
on the emerging relationship between dietary RS, the gut
microbiome and improved blood glucose levels [24–28].
It will not only characterise the changes to the maternal
gut microbiota in response to a higher dietary intake of
RS but proceed to identify any correlation between these
microbial changes and improvements in glycaemic control. Again, only a few studies have done this in non-pregnant populations. Additionally, it will investigate whether
maternal microbial changes in response to RS can alter
the microbiota of the neonate, possibly inoculating the
next generation with a more favourable microbiota. Also
unique to this study is the assessment of whether a high
dietary intake of RS from whole foods alone can improve
glycaemic control in GDM, or if an RS supplement is
required to achieve a positive result.
A limitation of this study is that food will not be provided to the participants which may limit compliance
with a high RS diet. However, a positive result would
indicate that this dietary intervention is a practical and
achievable intervention to incorporate into GDM management strategies. Periodic assessment of glucose is
also a limitation of the study as it only estimates overall glycaemic control but is the most frequently used
method in the management of GDM, whereas continuous blood glucose monitoring would assess the overall
exposure of the foetus to glucose. Funding for continuous blood glucose sensors is not yet available, therefore,
an opportunity to identify any overall glycaemic benefit
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through time-in-range values may be missed. The study
is adequately powered to detect improvements in
FBG and microbial changes (based on changes in faecal SCFA) but not for other outcomes such as rates of
LGA, macrosomia, neonatal hypoglycaemia and NICU
admissions.
This will be the first study to evaluate RS intervention in GDM management. If a high dietary intake of
RS is shown to favourably alter the GDM microbiome
and results in improved glycaemic control, this will
expand the dietary interventions available to manage
GDM without pharmacotherapy, reducing the burden
on the mother and the healthcare system. If a more
favourable maternal gut microbiota is found to persist
post-partum and is transferred to the neonate, longerterm health outcomes for mother and child may be
enhanced.
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